These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22736425)

  • 1. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
    Lee JH; Chung YH; Kim JA; Shim JH; Lee D; Lee HC; Shin ES; Yoon JH; Kim BI; Bae SH; Koh KC; Park NH
    Cancer; 2013 Jan; 119(1):136-42. PubMed ID: 22736425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study.
    Bozkurt Duman B; Kara B; Oguz Kara I; Demiryurek H; Aksungur E
    J BUON; 2011; 16(4):759-64. PubMed ID: 22331734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
    Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
    J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
    Woo HY; Heo J; Yoon KT; Kim GH; Kang DH; Song GA; Cho M
    Scand J Gastroenterol; 2012 Jul; 47(7):809-19. PubMed ID: 22563643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
    Hsu CH; Shen YC; Lin ZZ; Chen PJ; Shao YY; Ding YH; Hsu C; Cheng AL
    J Hepatol; 2010 Jul; 53(1):126-31. PubMed ID: 20416968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
    Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
    Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
    J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
    Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
    Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Staufer K; Fischer L; Seegers B; Vettorazzi E; Nashan B; Sterneck M
    Transpl Int; 2012 Nov; 25(11):1158-64. PubMed ID: 22882364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
    Kim JW; Lee JO; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Am J Clin Oncol; 2011 Apr; 34(2):125-9. PubMed ID: 20308869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib in advanced hepatocellular carcinoma.
    Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
    N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Rimassa L; Santoro A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
    Schmid I; Häberle B; Albert MH; Corbacioglu S; Fröhlich B; Graf N; Kammer B; Kontny U; Leuschner I; Scheel-Walter HG; Scheurlen W; Werner S; Wiesel T; von Schweinitz D
    Pediatr Blood Cancer; 2012 Apr; 58(4):539-44. PubMed ID: 21922643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
    Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
    Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
    Song T; Zhang W; Wu Q; Kong D; Ma W
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
    Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.